Myriad will present new data on its variant classification program at the ASHG annual meeting

Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will present four new studies at the American Society of Human Genetics Annual Meeting being held Oct. 18-22, 2016 in Vancouver, British Columbia. The research being presented highlights the clinical utility of Myriad’s myVision® Variant Classification Program and myRisk Hereditary Cancer gene panel test.

“Precision medicine is dependent on the accuracy of the information being provided to patients, and Myriad’s myVision is the most advanced variant classification program available to determine whether a patient's genetic mutation is benign or deleterious,” said Johnathan Lancaster, M.D., Ph.D, chief medical officer, Myriad Genetic Laboratories. “At ASHG, we are excited to present four new studies, which advance the state of the art of genetic testing and meet the scientific needs of researchers and clinicians.”

Below is a list of the featured presentations at ASHG (#ASHG2016):

Platform Presentations

Title: PMS2CL-hybrid Alleles Containing PMS2 Sequence and Other PMS2CL-derived Large Rearrangements: The Importance of Correct Interpretation of Dosage Alteration Analysis in PMS2.
Presenter: Nanda Singh.
Date: Thursday, October 20, 2016: 12:00 p.m. PT.
Platform: 137, Ballroom C.

Title: NGS Facilitates Identification of Retrotransposon Insertional Mutations in Hereditary Cancer Genes.
Presenter: Yaping Qian.
Date: Thursday, October 20, 2016: 12:45 p.m. PT.
Platform: 156, Room 115.

Poster Presentations

Title: Characterization of TP53 Sequencing Variants Initially Detected in Peripheral Blood Using Next Generation Sequencing Analysis.
Presenter: Debora Mancini-DiNardo.
Date: Wednesday, October 19, 2016: 2:00 – 3:00 p.m. PT.
Poster: 781W, Exhibit Hall B.

Title: Diagnostic Detection, Characterization & Classification of Partial Single Exon Deletions in Hereditary Cancer Genes.
Presenter: Benjamin Roa.
Date: Wednesday, October 19, 2016: 2:00 – 3:00 p.m. PT.
Poster: 763W, Exhibit Hall B.

For more information about these presentations, including a complete list of abstracts and presentations, please visit the ASHG website at http://www.ashg.org/2016meeting/.

About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, EndoPredict, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prolaris and GeneSight are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G